remain top diabet devic pick best product pipelin industri
softwar view best way invest cgm expect signific top-
bottom-lin upsid vs consensu expect grow appreci
non-intens type opportun drive share higher increas pt
dcf sale
believ make core growth hold attract
market dynam oligopoli technolog differenti top-tier
manag team scalabl profit model cgm market inflect
past two year expect annual volum growth next year
dxcm core intens market time expect cgm penetr entir
spectrum diabet care type type prediabet drive signific upsid vs long-
term expect view long-term non-intens type adopt question
best product pipelin industri hardwar softwar
believ best way invest secular growth industri
believ investor underappreci potenti magnitud upsid vs
expect see potenti revenu upsid
ep upsid increas revenu ep estim
respect forecast consensu respect
potenti non-intens type adopt move much faster expect
payer other third-parti softwar vendor alreadi lay
foundat long-term adopt competitive/market dynam investor often view
competit abbott zero-sum game howev believ
success near long term given vast market opportun limit addit
viabl competit scalabl profit busi expect
oper margin scale see potenti upsid vs current long term gross
quarterli updat includ result guidanc provid competitor
confer januari expect conserv initi guidanc particularli
profit given signific number growth opportun front
continu page
pleas see page report import disclosur
believ make core growth stori attract
market dynam technolog differenti top-tier manag team
scalabl profit model longer term price headwind exist howev non-
intens type adopt come fruition believ question volume/
revenue/profit upsid like signific even modest downsid price scenario
occur best product pipelin industri expect remain clear
cgm market leader forese futur wherev market goe
non-intens updat key partner
type cgm penetr continu
rapidli increas toward standard
care ou remain significantli
verg inflect next
growth forese futur
annual next year
revenu growth sustain pace
beyond
faster expect payer
signific gross margin upsid
scale
price declin faster
competitor close gap accuracy/
reliabl faster expect
found headquart san diego california medic devic
compani focus design develop commerci continu glucos
monitor cgm system use peopl diabet flagship offer today
dexcom system patient diabet detect trend track glucos
pattern move forward compani focus continu drive advanc
cgm technolog focus accuraci comfort connect longer term
goal drive cgm adopt across entir spectrum diabet care
product pipelin updat notabl launch expect limit launch
broad commerci launch critic gener robust growth
among intens manag type patient popul beyond key
year volum forecast wed also highlight updat dxcm softwar effort
pumper autom insulin deliveri algorithm pen user decis support
non-intens type updat potenti provid detail long
term type plan and/or scale type manag program
addit continu progress third parti softwar vendors/dxcm dont
expect new market type hospit etc impact financi result multipl
year howev investor begin believ long-term opportunity/account
within long-term dcf expect stock reflect valu financi
increas price target base dcf analysi includ long term
us non-intens type adopt geographi repres
sale line current sale multipl p/fcf share
alreadi quit run precipic gener signific cash
flow believ floor stock like higher believ see limit
long term price current forecast signific declin annual revenu per
patient next year amongst intens manag patient
remain abbott libr price today
worth note demonstr cost elast demand
market accordingli downsid price scenario would like least
somewhat off-set higher volum abt/dxcm would still like domin
launch delay whether driven difficulti scale manufactur someth els
delay launch beyond earli would clear neg impact
investor sentiment
competit headlines/launch abbott libr still like launch point
next month least sometim expect
approv icgm impli signific perform improv pend real world
data/feedback although expect accuracy/reli remain slightli behind
investor histor hyper-sensit competitor launches/headlin
compani report thomson eikon cowen compani
mm except per share day profit day gener oper non-gaap day day less long termnet earn per consensu estim mm except per share gross op cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
medic suppli devic diabet
risk diabet devic sector may includ regulatori process potenti delay
commerci launch new product potenti price pressur payor/cm
premium rel valuat competit high level invest need compet
make invest recommend earli stage diabet devic compani base
upon assess technolog probabl market success competit
regulatori reimburs etc potenti market opportun event
success howev compani lack tradit and/or matur financi
metric believ specif methodolog assign price target
risk includ limit cgm penetr fail increas competit product
reduc competit moat profit push back materi new product
releas delay due regulatori hurdl trade signific premium
